Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

thereby preventing the formation of Factor XIa. This approach is inspired by the natural deficiency of Factor XI, which is known to protect against thromboembolic conditions. "Novartis signs ...